Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion: From animal studies to clinical trials

Victor L. Serebruany, Dan Atar, Margaret R. Dalesandro, Christopher M. O'Connor, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

There has been some debate regarding the benefit of parenteral magnesium (Mg) in the treatment of acute myocardial infarction (AMI), due to conflicting results from animal studies and recent clinical trials. Several different hypotheses, proposing antiplatelet, and antithrombotic properties have been advanced to explain the cardioprotective properties of Mg during AMI. Although early clinical results were promising, there were serious flaws in the design and the logistics of small trials including out of date methodology, absence of control groups, and possible observer bias due to unblinded data collection. Moreover, the latest large-scale megatrial Fourth International Study of Infarct Survival (ISIS-4) provided conflicting data and caused major controversy, which will be difficult to resolve. Proponents of Mg therapy have suggested that the potential benefit was not seen in ISIS-4 because Mg was administered too late. Further clinical trials, well-designed, and carefully conducted, should elucidate possible benefits of parenteral Mg during myocardial injury, especially in conjunction with new and aggressive reperfusion techniques. The benefits of parenteral Mg in an expanding array of clinical conditions, including AMI, may be directly related to an improved hemostatic profile. This review summarizes the latest, and often confusing data on the effects of Mg on certain hemostatic characteristics which may be directly relevant to the existing controversy.

Original languageEnglish (US)
Pages (from-to)133-140
Number of pages8
JournalMagnesium research : official organ of the International Society for the Development of Research on Magnesium
Volume11
Issue number2
StatePublished - Jun 1998

Fingerprint

Myocardial Reperfusion
Hemostasis
Magnesium
Myocardial Ischemia
Animals
Clinical Trials
Myocardial Infarction
Hemostatics
Observer Variation
Reperfusion
Logistics
Control Groups
Defects
Wounds and Injuries

Keywords

  • Acute myocardial infarction
  • Animal model
  • Humans
  • Magnesium
  • Mechanisms
  • Myocardial ischemia-reperfusion

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion : From animal studies to clinical trials. / Serebruany, Victor L.; Atar, Dan; Dalesandro, Margaret R.; O'Connor, Christopher M.; Gurbel, Paul A.

In: Magnesium research : official organ of the International Society for the Development of Research on Magnesium, Vol. 11, No. 2, 06.1998, p. 133-140.

Research output: Contribution to journalArticle

@article{8ef375b4e5b04738b9a608285f3ca382,
title = "Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion: From animal studies to clinical trials",
abstract = "There has been some debate regarding the benefit of parenteral magnesium (Mg) in the treatment of acute myocardial infarction (AMI), due to conflicting results from animal studies and recent clinical trials. Several different hypotheses, proposing antiplatelet, and antithrombotic properties have been advanced to explain the cardioprotective properties of Mg during AMI. Although early clinical results were promising, there were serious flaws in the design and the logistics of small trials including out of date methodology, absence of control groups, and possible observer bias due to unblinded data collection. Moreover, the latest large-scale megatrial Fourth International Study of Infarct Survival (ISIS-4) provided conflicting data and caused major controversy, which will be difficult to resolve. Proponents of Mg therapy have suggested that the potential benefit was not seen in ISIS-4 because Mg was administered too late. Further clinical trials, well-designed, and carefully conducted, should elucidate possible benefits of parenteral Mg during myocardial injury, especially in conjunction with new and aggressive reperfusion techniques. The benefits of parenteral Mg in an expanding array of clinical conditions, including AMI, may be directly related to an improved hemostatic profile. This review summarizes the latest, and often confusing data on the effects of Mg on certain hemostatic characteristics which may be directly relevant to the existing controversy.",
keywords = "Acute myocardial infarction, Animal model, Humans, Magnesium, Mechanisms, Myocardial ischemia-reperfusion",
author = "Serebruany, {Victor L.} and Dan Atar and Dalesandro, {Margaret R.} and O'Connor, {Christopher M.} and Gurbel, {Paul A.}",
year = "1998",
month = "6",
language = "English (US)",
volume = "11",
pages = "133--140",
journal = "Magnesium Research",
issn = "0953-1424",
publisher = "John Libbey Eurotext",
number = "2",

}

TY - JOUR

T1 - Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion

T2 - From animal studies to clinical trials

AU - Serebruany, Victor L.

AU - Atar, Dan

AU - Dalesandro, Margaret R.

AU - O'Connor, Christopher M.

AU - Gurbel, Paul A.

PY - 1998/6

Y1 - 1998/6

N2 - There has been some debate regarding the benefit of parenteral magnesium (Mg) in the treatment of acute myocardial infarction (AMI), due to conflicting results from animal studies and recent clinical trials. Several different hypotheses, proposing antiplatelet, and antithrombotic properties have been advanced to explain the cardioprotective properties of Mg during AMI. Although early clinical results were promising, there were serious flaws in the design and the logistics of small trials including out of date methodology, absence of control groups, and possible observer bias due to unblinded data collection. Moreover, the latest large-scale megatrial Fourth International Study of Infarct Survival (ISIS-4) provided conflicting data and caused major controversy, which will be difficult to resolve. Proponents of Mg therapy have suggested that the potential benefit was not seen in ISIS-4 because Mg was administered too late. Further clinical trials, well-designed, and carefully conducted, should elucidate possible benefits of parenteral Mg during myocardial injury, especially in conjunction with new and aggressive reperfusion techniques. The benefits of parenteral Mg in an expanding array of clinical conditions, including AMI, may be directly related to an improved hemostatic profile. This review summarizes the latest, and often confusing data on the effects of Mg on certain hemostatic characteristics which may be directly relevant to the existing controversy.

AB - There has been some debate regarding the benefit of parenteral magnesium (Mg) in the treatment of acute myocardial infarction (AMI), due to conflicting results from animal studies and recent clinical trials. Several different hypotheses, proposing antiplatelet, and antithrombotic properties have been advanced to explain the cardioprotective properties of Mg during AMI. Although early clinical results were promising, there were serious flaws in the design and the logistics of small trials including out of date methodology, absence of control groups, and possible observer bias due to unblinded data collection. Moreover, the latest large-scale megatrial Fourth International Study of Infarct Survival (ISIS-4) provided conflicting data and caused major controversy, which will be difficult to resolve. Proponents of Mg therapy have suggested that the potential benefit was not seen in ISIS-4 because Mg was administered too late. Further clinical trials, well-designed, and carefully conducted, should elucidate possible benefits of parenteral Mg during myocardial injury, especially in conjunction with new and aggressive reperfusion techniques. The benefits of parenteral Mg in an expanding array of clinical conditions, including AMI, may be directly related to an improved hemostatic profile. This review summarizes the latest, and often confusing data on the effects of Mg on certain hemostatic characteristics which may be directly relevant to the existing controversy.

KW - Acute myocardial infarction

KW - Animal model

KW - Humans

KW - Magnesium

KW - Mechanisms

KW - Myocardial ischemia-reperfusion

UR - http://www.scopus.com/inward/record.url?scp=0032088418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032088418&partnerID=8YFLogxK

M3 - Article

C2 - 9675757

AN - SCOPUS:0032088418

VL - 11

SP - 133

EP - 140

JO - Magnesium Research

JF - Magnesium Research

SN - 0953-1424

IS - 2

ER -